Fresenius Medical Care AG & Co. (FMS) Receives “Buy” Rating from Nord/LB

Fresenius Medical Care AG & Co. (NYSE:FMS)‘s stock had its “buy” rating reaffirmed by investment analysts at Nord/LB in a research report issued on Tuesday.

FMS has been the topic of several other reports. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating and set a $53.00 price objective on the stock in a research report on Monday, October 9th. DZ Bank restated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, December 18th. Morgan Stanley downgraded Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research report on Monday, December 11th. SunTrust Banks set a $62.00 price objective on Fresenius Medical Care AG & Co. and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, Royal Bank of Canada restated a “hold” rating and issued a $44.00 price objective on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $53.00.

Fresenius Medical Care AG & Co. (FMS) opened at $52.55 on Tuesday. Fresenius Medical Care AG & Co. has a 52-week low of $39.46 and a 52-week high of $52.96. The company has a market capitalization of $32,270.43, a PE ratio of 23.57, a PEG ratio of 2.36 and a beta of 0.45. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.22 and a quick ratio of 0.98.

Several institutional investors have recently made changes to their positions in FMS. UBS Asset Management Americas Inc. lifted its position in shares of Fresenius Medical Care AG & Co. by 3.6% in the second quarter. UBS Asset Management Americas Inc. now owns 2,357 shares of the company’s stock worth $114,000 after buying an additional 81 shares in the last quarter. Pacer Advisors Inc. purchased a new stake in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $179,000. HPM Partners LLC purchased a new stake in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $221,000. YorkBridge Wealth Partners LLC lifted its position in shares of Fresenius Medical Care AG & Co. by 19.4% in the second quarter. YorkBridge Wealth Partners LLC now owns 4,613 shares of the company’s stock worth $222,000 after buying an additional 749 shares in the last quarter. Finally, Stifel Financial Corp purchased a new stake in shares of Fresenius Medical Care AG & Co. in the second quarter worth about $225,000. Institutional investors and hedge funds own 3.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/02/fresenius-medical-care-ag-co-fms-receives-buy-rating-from-nordlb.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply